Related Experiment Video
Updated: Dec 17, 2025

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Reducing Senescent Cell Burden in Aging and Disease
Robert J Pignolo1, João F Passos1, Sundeep Khosla1
1Mayo Clinic Departments of Medicine, Physiology and Biomedical Engineering, and the Kogod Center on Aging, Rochester, MN, USA.
Abstract:
Cellular senescence is a primary aging process and tumor suppressive mechanism characterized by irreversible growth arrest, apoptosis resistance, production of a senescence-associated secretory phenotype (SASP), mitochondrial dysfunction, and alterations in DNA and chromatin. In preclinical aging models, accumulation of senescent cells is associated with multiple chronic diseases and disorders, geriatric syndromes, multimorbidity, and accelerated aging phenotypes. In animals, genetic and pharmacologic reduction of senescent cell burden results in the prevention, delay, and/or alleviation of a variety of aging-related diseases and sequelae. Early clinical trials have thus far focused on safety and target engagement of senolytic agents that clear senescent cells. We hypothesize that these pharmacologic interventions may have transformative effects on geriatric medicine.
Insights
Cellular senescence, a key aging process, drives age-related diseases. Clearing senescent cells with senolytic drugs shows promise for improving healthspan and treating geriatric conditions.
Area of Science:
- Gerontology and Cellular Biology
- Molecular Biology and Aging Research
Background:
- Cellular senescence is a fundamental aging process and a tumor suppressive mechanism.
- Senescent cells accumulate with age, contributing to chronic diseases, geriatric syndromes, and multimorbidity.
- This accumulation is linked to accelerated aging phenotypes in preclinical models.
Purpose of the Study:
- To explore the potential of reducing senescent cell burden to prevent or alleviate aging-related diseases.
- To investigate the hypothesis that pharmacologic interventions targeting senescent cells could transform geriatric medicine.
Main Methods:
- Preclinical studies involving genetic and pharmacologic reduction of senescent cell burden in animal models.
- Review of early-phase clinical trials assessing the safety and target engagement of senolytic agents.
Main Results:
- Reduction of senescent cells in animals prevented, delayed, or alleviated various aging-related diseases.
- Early clinical trials are evaluating senolytic agents for safety and efficacy.
Conclusions:
- Targeting cellular senescence holds significant therapeutic potential for age-related conditions.
- Senolytic therapies may offer transformative benefits for geriatric medicine and human healthspan.
More Related Videos
Related Concept Videos
Replicative Cell Senescence
Aging
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
iPS Cell Differentiation
The Effect of Aging on Tissues
Mitochondria

